We will summarize written responses to this notice and address them in our submission for OMB approval. As a result of your comments, we will make any necessary adjustments to the burden in our submission to OMB.

Public Comment Procedures: Before including your address, phone number, email address, or other personal identifying information in your comment, you should be aware that your entire comment—including your personal identifying information—may be made publicly available at any time. While you can ask us in your comment to withhold your personal identifying information from public review, we cannot guarantee that we will be able to do so.

BSEE Information Collection Clearance Officer: Nicole Mason (703) 787–1607.

Dated: June 3, 2016.
Robert W. Middleton,
Deputy Chief, Office of Offshore Regulatory Programs.

AGENCY HOLDING THE MEETING:
Sunshine Act Meeting

COMMISSION:
International Trade Commission

PROGRAMS:

Matters to be considered:
1. Agendas for future meetings: None.
2. Minutes.
3. Ratification List.
4. Vote in Inv. Nos. 701–TA–541 and 731–TA–1284 and 1286 (Final) (Cold-Rolled Steel Flat Products from China and Japan). The Commission is currently scheduled to complete and file its determinations and views of the Commission on July 5, 2016.
5. Outstanding action jackets: None.

In accordance with Commission policy, subject matter listed above, not disposed of at the scheduled meeting, may be carried over to the agenda of the following meeting.

By order of the Commission.
Issued: June 8, 2016.
William R. Bishop,
Supervisory Hearings and Information Officer.

BILLING CODE 7020–02–P

INTERNATIONAL TRADE COMMISSION

[USITC SE–16–020]

Sunshine Act Meeting


TIME AND DATE: June 22, 2016 at 11:00 a.m.


STATUS: Open to the public.

MATTERS TO BE CONSIDERED:
1. Agendas for future meetings: None.
2. Minutes.
3. Ratification List.
4. Vote in Inv. Nos. 701–TA–541 and 731–TA–1284 and 1286 (Final) (Cold-Rolled Steel Flat Products from China and Japan). The Commission is currently scheduled to complete and file its determinations and views of the Commission on July 5, 2016.
5. Outstanding action jackets: None.

In accordance with Commission policy, subject matter listed above, not disposed of at the scheduled meeting, may be carried over to the agenda of the following meeting.

By order of the Commission.
Issued: June 8, 2016.
William R. Bishop,
Supervisory Hearings and Information Officer.

BILLING CODE 7020–02–P

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

[Docket No. DEA–392]

Bulk Manufacturer of Controlled Substances Application: Sigma Aldrich Research Biochemicals, Inc.

**ACTION:** Notice of application.

**DATES:** Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration in accordance with 21 CFR 1301.33(a) on or before August 12, 2016.

**ADDRESSES:** Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/ODW, 8701 Morrissette Drive, Springfield, Virginia 22152.

**SUPPLEMENTARY INFORMATION:** The Attorney General has delegated her authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, dispensers, importers, and exporters of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Deputy Assistant Administrator of the DEA Office of Diversion Control (“Deputy Assistant Administrator”) pursuant to section 7 of 28 CFR part 0, appendix to subpart R.

In accordance with 21 CFR 1301.33(a), this is notice that on February 1, 2016, Sigma Aldrich Research Biochemicals, Inc., 1–3 Strathmore Road, Natick, Massachusetts 01760–2447 applied to be registered as a bulk manufacturer of the following basic classes of controlled substances:

<table>
<thead>
<tr>
<th>Controlled substance</th>
<th>Schedule</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cathinone (1235)</td>
<td></td>
</tr>
<tr>
<td>Methcathinone (1237)</td>
<td></td>
</tr>
<tr>
<td>Mephedrone (4-Methyl-N-methylcathinone) (1248)</td>
<td></td>
</tr>
<tr>
<td>Aminorex (1585)</td>
<td></td>
</tr>
<tr>
<td>Alpha-ethyltryptamine (7248)</td>
<td></td>
</tr>
<tr>
<td>Lysergic acid diethylamide (7315)</td>
<td></td>
</tr>
<tr>
<td>Tetrahydrocannabinols (7370)</td>
<td></td>
</tr>
<tr>
<td>4-Bromo-2,5-dimethoxyamphetamine (7391)</td>
<td></td>
</tr>
<tr>
<td>4-Bromo-2,5-dimethoxyphenethylamine (7392)</td>
<td></td>
</tr>
<tr>
<td>4-Methyl-2,5-dimethoxyamphetamine (7395)</td>
<td></td>
</tr>
<tr>
<td>2,5-Dimethoxyamphetamine (7396)</td>
<td></td>
</tr>
<tr>
<td>3,4-Methylenedioxyamphetamine (7400)</td>
<td></td>
</tr>
</tbody>
</table>